The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Cell and Gene Therapy Bioassay Services Market by Type of Therapy (Cell Therapy and Gene Therapy), Therapeutic Area (Oncological, Infectious, Autoimmune, Rare / Genetic, Cardiovascular, Metabolic, Blood, Neurological, Ophthalmic Disorders and Other Therapeutic Areas), Scale of Operation (Discovery, Preclinical and Clinical) and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    November 2021

  • Pages
    310

  • View Count
    290

Example Insights

Cell-and-Gene-Therapy-Bioassay-Service-Market-Context Cell-and-Gene-Therapy-Bioassay-Service-Market-List-of-Service-Providers Cell-and-Gene-Therapy-Bioassay-Service-Market-Distribution-by-Year-of-Establishment
Cell-and-Gene-Therapy-Bioassay-Service-Market-Geographical-Distribution Cell-and-Gene-Therapy-Bioassay-Service-Market-Key-Offerings Cell-and-Gene-Therapy-Bioassay-Service-Market-Global-Strategic-Initiatives
Cell-and-Gene-Therapy-Bioassay-Service-Market-Case-Study Cell-and-Gene-Therapy-Bioassay-Service-Market-Potential-Strategic-Partners Cell-and-Gene-Therapy-Bioassay-Service-Market-Distribution-by-Therapeutic-Area

Overview

Given the various advantages of cell and gene therapies and their ability to address the underlying causes of serious clinical conditions, the preference for such therapeutic modalities has increased over the years. As a result, several cell and gene therapies have been developed and approved for the treatment of a wide range of disease indications. In fact, at the time of this report’s publication, more than 30 such therapies had been approved and over 1,200 therapeutic leads are under evaluation in different stages. Owing to their rising popularity, these upcoming advanced therapeutic products are on the verge of becoming one of the highest valued therapeutic segments within the biopharmaceutical industry. Having said that, as is the case for all biological products, the development of cell and gene therapies is a complex, challenging and cost intensive process. Outsourcing is, therefore, a preferred operational model, with cell and gene therapy innovators relying heavily on specialty contract service providers to handle various aspects of their product development and manufacturing operations. In fact, over three quarters of the biopharmaceutical companies prefer to outsource their operations to the contract service providers and a large part of their expenditure goes to outsourcing services. Amongst the various operations, the outsourcing of analytical testing services, including environment testing, bioanalytical testing, analytical testing, chemistry and stability testing, method development and validation, and product characterization, has witnessed significant rise in recent years.  

The rising demand for outsourcing bioanalytical services has prompted the emergence of several contract research organizations that claim to offer bioassay services for cell and gene therapies. These companies usually have relatively more experience and are well equipped with the instruments and technological platforms to offer both pre-developed and customized bioassays. In fact, these companies assist in bringing out the maximum efficiency of study design by offering several cost benefits and reducing the associated timelines. Given the benefits of outsourcing the bioassay services and the ongoing efforts of service providers to further improve / expand their respective offerings, we believe that the cell and gene therapy bioassay services market is likely to evolve at a steady pace, till 2030.

Scope of the Report

The “Cell and Gene Therapy Bioassay Services Market by Type of Therapy (Cell Therapy and Gene Therapy), Therapeutic Area (Oncological Disorders, Infectious Diseases, Autoimmune Disorders, Rare / Genetic Disorders, Cardiovascular Disorders, Metabolic Disorders, Blood Disorders, Neurological Disorders, Ophthalmic Disorders and Other Therapeutic Areas), Scale of Operation (Discovery, Preclinical and Clinical) and Geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current landscape and the likely future potential of cell and gene therapy bioassay service providers, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes:

  • A detailed assessment of the overall market landscape of the cell and gene therapy bioassay services market, providing information on their year of establishment, company size, location of headquarters, location of bioanalytical facilities, type of offering (in vitro and in vivo), type of bioassay(s) offered (pre-developed assay and customized assay), type of bioanalytical services (immunoassay, potency assay, qualitative PCR, digital droplet PCR, flow cytometry, ELISA, immunochemistry and others) and application area (cell therapy, gene therapy and others).
  • A detailed competitiveness analysis of the cell and gene therapy bioassay service providers based in different geographies, by taking into consideration their service strength (in terms of bioassay offering(s) and number of bioanalytical services offered), service applicability (in terms of number of bioassays offered and application area) and supplier strength (in terms of years of experience in this field and company size).
  • Tabulated profiles of key players offering a wide range of cell and gene therapy bioassay services across North America, Europe and Asia-Pacific. Each profile includes an overview of the company, financial information (if available), details of its cell and gene therapy bioassay services portfolio, types of offerings, type of bioassay(s) offered, types of bioanalytical services offered, application area, location of bioanalytical facilities, recent developments and an informed future outlook. 
  • An insightful contemporary market trend analysis, featuring the distribution of cell and gene therapy service providers by type of bioanalytical services offered and application area and an analysis of cell and gene therapy service providers, based on type of bioassay and types of bioanalytical services offered. Further, the chapter also features a schematic world map representation, highlighting the location of bioanalytical facilities of cell and gene therapy bioassay service providers. 
  • A detailed analysis of the global events attended by the service providers, based on year of event, type of event, type of services involved and application area, and strategic initiatives taken by various cell and gene therapy bioassay service providers. 
  • A case study of the overall landscape of cell and gene therapy therapeutics market, based on a number of parameters. The market landscape of cell therapies, features distribution of cell therapies across phase of development, therapeutic area and type of developer. Further, the market landscape of cell therapies, features distribution of gene therapies across phase of development of pipeline candidates and key therapeutic areas. The chapter also features information on the developers involved in the domain of cell and gene therapies.
  • An in-depth analysis of more than 260 cell therapy developers that are anticipated to partner with cell and gene therapy bioassay service providers and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other cell therapy capabilities.
  • An in-depth analysis of nearly 190 gene therapy developers that are anticipated to partner with cell and gene therapy bioassay service providers and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of cell and gene therapy bioassay services market. We have provided an informed estimate of the evolution of the market for the period 2021-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of therapy (cell therapy and gene therapy), [B] therapeutic area (oncological disorders, infectious diseases, autoimmune disorders, rare / genetic disorders, cardiovascular disorders, metabolic disorders, blood disorders, neurological disorders, ophthalmic disorders and other therapeutic areas), [C] scale of operation (discovery, preclinical and clinical) and [D] geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report are backed by a deep understanding of key insights generated from both secondary and primary research. The information presented in this study was also influenced by discussions held with senior stakeholders in this industry.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading services providers offering bioassay services related to cell and gene therapies?
  • What is the relative competitiveness of different cell and gene therapy bioassay service providers?
  • Which is the commonly offered bioanalytical service (immunoassay, potency assay, qualitative PCR, digital droplet PCR, flow cytometry, ELISA, immunochemistry and others) related to cell and gene therapy?
  • What are the key trends within the cell and gene therapy bioassay service providers market?
  • What kind of initiatives are being taken by stakeholders engaged in this domain?
  • Which players are likely to partner with cell and gene therapy bioassay service providers?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to teleradiology services market?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the cell and gene therapy bioassay services market and its likely evolution in the short to mid-term and long term.

Chapter 3 provides a general introduction to bioassays and type of cell and gene therapy bioassays. It also highlights the importance of bioassay and challenges related to cell and gene therapy bioassays. Additionally, it provides a brief introduction to the concept of CROs, featuring a discussion on the role of contract service providers and prevalent outsourcing trends.

Chapter 4 provides a detailed assessment of the overall market landscape of cell and gene therapy bioassay service providers, including information on close to 50 stakeholders and a detailed analysis based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, location of bioanalytical facilities, type of bioassay(s) offered (in vitro and in vivo), type of offerings (pre-developed assay and customized assay), type of bioanalytical services (immunoassay, potency assay, qualitative PCR, digital droplet PCR, flow cytometry, ELISA, immunochemistry and others) and application area (cell therapy, gene therapy and others).

Chapter 5 features an insightful competitiveness analysis of the cell and gene therapy bioassay service providers based in different geographies, based on service strength (in terms of number of offering(s) of bioassays and number of bioanalytical services offered), service applicability (in terms of number of bioassays offered and application area) and supplier strength (in terms of years of experience in this field and company size).

Chapter 6 features tabulated profiles of key players offering a wide range of cell and gene therapy bioassay services across North America. Each profile includes an overview of the company, financial (if available), details of its cell and gene therapy bioassay services portfolio, types of bioassay(s) offered, types of offerings, type of bioanalytical services offered, application area, location of bioanalytical facilities, recent developments and an informed future outlook.

Chapter 7 features tabulated profiles of key players offering a wide range of cell and gene therapy bioassay services across Europe and Asia-Pacific. Each profile includes an overview of the company, financial information (if available), details of its cell and gene therapy bioassay services portfolio, types of bioassay(s) offered, types of offerings, types of bioanalytical services offered, application area, location of bioanalytical facilities, recent developments and an informed future outlook.

Chapter 8 includes a contemporary market trend analysis, featuring the distribution of cell and gene therapy service providers by type of bioanalytical services offered and application area and an analysis of cell and gene therapy service providers, based on type of bioassay and type of bioanalytical services offered. Further, the chapter also features a schematic world map representation, highlighting the location of bioanalytical facilities of cell and gene therapy bioassay service providers.

Chapter 9 includes a detailed analysis of the global events and strategic initiatives taken by the several cell and gene therapy bioassay service providers related to bioassays. The chapter features distribution of events on the basis of year of event, type of event, type of services involved and application area. 

Chapter 10 is a case study of the overall landscape of cell and gene therapy therapeutics market, based on number of relevant parameters, such as phase of development, therapeutic area and type of developer, while highlighting key developers. The chapter also features information on the companies involved in the development of cell and gene therapies.

Chapter 11 features an in-depth analysis of more than 260 cell therapy developers that are anticipated to partner with cell and gene therapy bioassay service providers and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other cell therapy capabilities.

Chapter 12 features an in-depth analysis of more than 190 gene therapy developers that are anticipated to partner with cell and gene therapy bioassay service providers and have been shortlisted on the basis of several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) and availability of other gene therapy capabilities.

Chapter 13 features an insightful market forecast analysis, highlighting the likely growth of the cell and gene therapy services market for the time period 2021-2030. In order to provide details on the future outlook, our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] type of therapy (cell therapy and gene therapy), [B] therapeutic area (oncological disorders, infectious diseases, autoimmune disorders, rare / genetic disorders, cardiovascular disorders, metabolic disorders, blood disorders, neurological disorders, ophthalmic disorders and other therapeutic areas), [C] scale of operation (discovery, preclinical and clinical) and [D] geography (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 14 is a summary of the overall report, presenting the insights on the contemporary market trends and the likely evolution of the cell and gene therapy bioassay services market. 

Chapter 15 is a collection of interview transcripts of discussions held with various key stakeholders in this market.

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Bioassays
3.3. Cell and Gene Therapy Bioassays
3.4. Importance of Bioassays in Cell and Gene Therapy
3.5. Challenges Related to Cell and Gene Therapy Bioassays
3.6. Role of Contract Service Providers and Prevalent Outsourcing Trends
3.7. Future Perspectives
 

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Cell and Gene Therapy Bioassay Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Location of Bioanalytical Facilities
4.2.6. Analysis by Type of Bioassay(s) Offered
4.2.7. Analysis by Types of Offering(s) of Bioassay
4.2.8. Analysis of Type of Bioanalytical Service(s) Offered
4.2.9. Analysis by Application Area

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Key Parameters
5.4. Competitiveness Analysis: Companies Offering Cell and Gene Therapy Bioassay Services in North America
5.5. Competitiveness Analysis: Companies Offering Cell and Gene Therapy Bioassay Services in Europe and Asia-Pacific

6. CELL AND GENE THERAPY BIOASSAY SERVICE PROVIDERS IN NORTH AMERICA: COMPANY PROFILES
6.1. Chapter Overview
6.2. CCRM
6.2.1. Company Overview
6.2.2. Cell and Gene Therapy Bioassay Service Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Nexelis
6.3.1. Company Overview
6.3.2. Cell and Gene Therapy Bioassay Service Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. Pacific BioLabs
6.4.1. Company Overview
6.4.2. Cell and Gene Therapy Bioassay Service Portfolio
6.4.3. Recent Developments and Future Outlook

6.5. PPD Laboratories
6.5.1. Company Overview
6.5.2. Cell and Gene Therapy Bioassay Service Portfolio
6.5.3. Recent Developments and Future Outlook

6.6. WuXi Advanced Therapies
6.6.1. Company Overview
6.6.2. Cell and Gene Therapy Bioassay Service Portfolio
6.6.3. Recent Developments and Future Outlook

7. CELL AND GENE THERAPY BIOASSAY SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC: COMPANY PROFILES
7.1. Chapter Overview
7.2. AnaBioTec
7.2.1. Company Overview
7.2.2. Cell and Gene Therapy Bioassay Service Portfolio
7.2.3. Recent Developments and Future Outlook

7.3. Intertek Pharmaceutical Services
7.3.1. Company Overview
7.3.2. Cell and Gene Therapy Bioassay Service Portfolio
7.3.3. Recent Developments and Future Outlook

7.4. Lonza
7.4.1. Company Overview
7.4.2. Cell and Gene Therapy Bioassay Service Portfolio
7.4.3. Recent Developments and Future Outlook

7.5. Porton Bio
7.5.1. Company Overview
7.5.2. Cell and Gene Therapy Bioassay Service Portfolio
7.5.3. Recent Developments and Future Outlook

8. MARKET TREND ANALYSIS
8.1. Chapter Overview
8.2 Cell and Gene Therapy Bioassay Service Providers: Analysis by Type of Bioanalytical Service(s) Offered and Application Area
8.3. Cell and Gene Therapy Bioassay Service Providers: Analysis by Type of Bioassay(s) and Type of Bioanalytical Service(s) Offered
8.4 Cell and Gene Therapy Bioassay Service Providers: Analysis by Location of Bioanalytical facilities
8.4.1. Players with Bioanalytical Facilities in US
8.4.2. Players with Bioanalytical Facilities in Rest of the World

9. GLOBAL EVENT AND STRATEGIC INITIATIVE ANALYSIS
9.1. Chapter Overview
9.2. Cell and Gene Therapy Bioassay Service Providers: List of Event and Strategic Initiatives
9.2.1. Analysis by Year of Event
9.2.2. Analysis by Type of Event
9.2.3. Analysis by Year and Type of Event
9.2.4. Analysis by Type of Services Involved
9.2.5. Analysis by Application Area
9.2.6. Prominent Players: Analysis by Number of Events and Strategic Initiatives

10. CASE STUDY: MARKET LANDSCAPE OF CELL AND GENE THERAPIES
10.1. Chapter Overview
10.2. Cell Therapy Market
10.2.1. T-Cell Immunotherapies: Development Pipeline
10.2.1.1. Analysis by Type of Product

10.2.2. CAR-T Cell Therapies: Development Pipeline
10.2.2.1. Analysis by Phase of Development
10.2.2.2. Analysis by Therapeutic Area
10.2.2.3. Analysis by Type of Developer
10.2.2.4. Key Industry Players: Analysis by Number of CAR-T Cell Therapies in Development

10.2.3. TCR-based Therapies: Development Pipeline
10.2.3.1. Analysis by Phase of Development
10.2.3.2. Analysis by Therapeutic Area
10.2.3.3. Analysis by Type of Developer
10.2.3.4. Key Industry Players: Analysis by Number of TCR-based Therapies in Development

10.2.4. TIL-based Therapies: Development Pipeline
10.2.4.1. Analysis by Phase of Development
10.2.4.2. Analysis by Therapeutic Area
10.2.4.3. Analysis by Type of Developer
10.2.4.4. Key Industry Players: Analysis by Number of TIL-based Therapies in Development

10.3. Gene Therapy Market
10.3.1. Gene Therapy Market: Clinical and Commercial Pipeline
10.3.1.1. Analysis by Phase of Development
10.3.1.2. Analysis by Therapeutic Area

10.3.2. Gene Therapy Market: Development Pipeline
10.3.2.1. Analysis by Phase of Development
10.3.2.2. Analysis by Therapeutic Area

11. LIKELY PARTNERS FOR CELL THERAPY BIOASSAY SERVICE PROVIDERS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Potential Strategic Partners for Cell Therapy Bioassay Service Providers
11.3.1. Likely Partner Opportunities for Stem Cell Therapy Bioassay Service Providers
11.3.2. Likely Partner Opportunities for CAR-T Therapy Bioassay Service Providers
11.3.3. Likely Partner Opportunities for Dendritic Cell Therapy Bioassay Service Providers
11.3.4. Likely Partner Opportunities for Tumor Cell Therapy Bioassay Service Providers
11.3.5. Likely Partner Opportunities for NK Cell Therapy Bioassay Service Providers

12. LIKELY PARTNERS FOR GENE THERAPY BIOASSAY SERVICE PROVIDERS
12.1. Chapter Overview
12.2. Scope and Methodology

12.3. Potential Strategic Partners for Gene Therapy Bioassay Service Providers
12.3.1. Likely Partner Opportunities in North America
12.3.2. Likely Partner Opportunities in Europe
12.3.3. Likely Partner Opportunities in Asia-Pacific

13. MARKET FORECAST AND OPPORTUNITY ANALYSIS

13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Global Cell and Gene Therapy Bioassay Services Market
13.3.1. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Type of Therapy
13.3.2. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Therapeutic Area
13.3.3. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Scale of Operation
13.3.4. Global Cell and Gene Therapy Bioassay Services Market: Distribution by Geography

13.4. Cell Therapy Bioassay Services Market in North America, 2021-2030
13.4.1. Cell Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2030
13.4.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2030
13.4.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2030
13.4.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2030
13.4.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2030
13.4.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2030
13.4.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2030
13.4.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2030
13.4.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2030
13.4.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2030
13.4.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2030
13.4.2. Cell Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2030
13.4.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2030
13.4.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2030
13.4.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2030

13.5. Cell Therapy Bioassay Services Market in Europe, 2021-2030
13.5.1. Cell Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2030
13.5.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2030
13.5.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2030
13.5.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2030
13.5.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2030
13.5.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2030
13.5.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2030
13.5.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2030
13.5.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2030
13.5.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2030
13.5.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2030
13.5.2. Cell Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2030
13.5.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2030
13.5.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2030
13.5.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in Europe, 2021-2030

13.6. Cell Therapy Bioassay Services Market in Asia-Pacific, 2021-2030
13.6.1. Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2030
13.6.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2030
13.6.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2030
13.6.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030
13.6.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2030
13.6.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030
13.6.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2030
13.6.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2030
13.6.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2030
13.6.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2030
13.6.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030
13.6.2. Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2030
13.6.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2030
13.6.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2030
13.6.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2030

13.7. Cell Therapy Bioassay Services Market in Latin America, 2021-2030
13.7.1. Cell Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2030
13.7.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2030
13.7.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2030
13.7.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2030
13.7.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2030
13.7.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2030
13.7.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2030
13.7.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2030
13.7.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2030
13.7.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2030
13.7.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2030
13.7.2. Cell Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2030
13.7.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2030
13.7.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2030
13.7.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2030

13.8. Cell Therapy Bioassay Services Market in MENA, 2021-2030
13.8.1. Cell Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2030
13.8.1.1. Cell Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2030
13.8.1.2. Cell Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2030
13.8.1.3. Cell Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2030
13.8.1.4. Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2030
13.8.1.5. Cell Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2030
13.8.1.6. Cell Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2030
13.8.1.7. Cell Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2030
13.8.1.8. Cell Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2030
13.8.1.9. Cell Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2030
13.8.1.10. Cell Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2030
13.8.2. Cell Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2030
13.8.2.1. Cell Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2030
13.8.2.2. Cell Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2030
13.8.2.3. Cell Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2030

13.9. Gene Therapy Bioassay Services Market in North America, 2021-2030
13.9.1. Gene Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2030
13.9.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2030
13.9.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2030
13.9.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2030
13.9.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2030
13.9.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2030
13.9.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2030
13.9.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2030
13.9.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2030
13.9.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2030
13.9.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2030
13.9.2. Gene Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2030
13.9.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2030
13.9.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2030
13.9.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2030

13.10. Gene Therapy Bioassay Services Market in Europe, 2021-2030
13.10.1. Gene Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2030
13.10.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2030
13.10.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2030
13.10.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2030
13.10.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2030
13.10.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2030
13.10.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2030
13.10.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2030
13.10.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2030
13.10.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2030
13.10.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2030
13.10.2. Gene Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2030
13.10.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2030
13.10.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2030
13.10.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in Europe, 2021-2030

13.11. Gene Therapy Bioassay Services Market in Asia-Pacific, 2021-2030
13.11.1. Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2030
13.11.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2030
13.11.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2030
13.11.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030
13.11.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2030
13.11.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030
13.11.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2030
13.11.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2030
13.11.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2030
13.11.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2030
13.11.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030
13.11.2. Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2030
13.11.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2030
13.11.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2030
13.11.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2030

13.12. Gene Therapy Bioassay Services Market in Latin America, 2021-2030
13.12.1. Gene Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2030
13.12.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2030
13.12.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2030
13.12.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2030
13.12.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2030
13.12.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2030
13.12.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2030
13.12.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2030
13.12.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2030
13.12.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2030
13.12.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2030
13.12.2. Gene Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2030
13.12.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2030
13.12.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2030
13.12.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2030

13.13. Gene Therapy Bioassay Services Market in MENA, 2021-2030
13.13.1. Gene Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2030
13.13.1.1. Gene Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2030
13.13.1.2. Gene Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2030
13.13.1.3. Gene Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2030
13.13.1.4. Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2030
13.13.1.5. Gene Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2030
13.13.1.6. Gene Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2030
13.13.1.7. Gene Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2030
13.13.1.8. Gene Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2030
13.13.1.9. Gene Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2030
13.13.1.10. Gene Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2030
13.13.2. Gene Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2030
13.13.2.1. Gene Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2030
13.13.2.2. Gene Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2030
13.13.2.3. Gene Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2030

14. CONCLUSION
14.1. Chapter Overview

15. EXECUTIVE INSIGHTS

16. APPENDIX 1: TABULATED DATA

17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Current Market Landscape of Cell and Gene Therapy Bioassay Service providers
Figure 2.2 Executive Summary: Clinical / Preclinical Pipeline of Cell and Gene Therapies
Figure 2.3 Executive Summary: Global Event and Strategic Analysis
Figure 2.4 Executive Summary: Market and Opportunity Analysis
Figure 3.1 Types of Cell and Gene Therapy Bioassays
Figure 4.1 Cell and Gene Therapy Bioassay Service Providers: Distribution by Year of Establishment
Figure 4.2 Cell and Gene Therapy Bioassay Service Providers: Distribution by Company Size
Figure 4.3 Cell and Gene Therapy Bioassay Service Providers: Distribution by Location of Headquarters
Figure 4.4 Cell and Gene Therapy Bioassay Service Providers: Distribution by Location of Bioanalytical Facilities
Figure 4.5 Cell and Gene Therapy Bioassay Service Providers: Distribution by Type of Bioassay(s) Offered
Figure 4.6 Cell and Gene Therapy Bioassay Service Providers: Distribution by Type of Offering(s)
Figure 4.7 Cell and Gene Therapy Bioassay Service Providers: Distribution by Type of Bioanalytical Service(s) Offered
Figure 4.8 Cell and Gene Therapy Bioassay Service Providers: Distribution by Application Area(s)
Figure 5.5 Company Competitiveness Analysis: Cell and Gene Therapy Service Providers in North America
Figure 5.6 Company Competitiveness Analysis: Cell and Gene Therapy Service Providers in Europe and Asia-Pacific
Figure 8.1 Cell and Gene Therapy Bioassay Service Providers: Distribution by Type of Bioanalytical Service(s) Offered and Application Area
Figure 8.2 Cell and Gene Therapy Bioassay Service Providers: Distribution by Type of Bioassay(s) and Type of Bioanalytical Service(s) Offered
Figure 8.3 Cell and Gene Therapy Bioassay Service Providers: Distribution of Players with Bioanalytical Facilities in the US
Figure 8.4 Cell and Gene Therapy Bioassay Service Providers: Distribution of Players with Bioanalytical Facilities in Rest of the World
Figure 9.1 Global Events and Strategic Initiatives: Distribution by Year of Event, 2017-2021 (till September)
Figure 9.2 Global Events and Strategic Initiatives: Distribution by Types of Events, 2017-2021 (till September)
Figure 9.3 Global Events and Strategic Initiatives: Distribution by Year and Types of Events, 2017-2021 (till September)
Figure 9.4 Global Events and Strategic Initiatives: Distribution by Types of Services Involved, 2017-2021 (till September)
Figure 9.5 Global Events and Strategic Initiatives: Distribution by Application Area, 2017-2021 (till September)
Figure 9.6 Global Events and Strategic Initiatives: Distribution by Prominent Players, 2017-2021 (till September)
Figure 10.1 T-Cell Immunotherapies: Type of Product
Figure 10.2 CAR-T Cell Therapies: Distribution by Phase of Development
Figure 10.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 10.4 CAR-T Cell Therapies: Distribution by Type of Developer
Figure 10.5 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 10.6 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 10.7 TCR-based Therapies: Distribution by Phase of Development
Figure 10.8 TCR-based Therapies: Distribution by Therapeutic Area
Figure 10.9 TCR-based Therapies: Distribution by Type of Developer
Figure 10.10 TCR-based Therapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 10.11 TCR-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 10.12 TIL-based Therapies: Distribution by Phase of Development
Figure 10.13 TCR-based Therapies: Distribution by Therapeutic Area
Figure 10.14 TIL-based Therapies: Distribution by Type of Developer
Figure 10.15 TIL-based Therapies: Active Industry Players by Number of Therapies in Clinical Development
Figure 10.16 TIL-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Figure 10.17 Gene Therapies: Distribution by Phase of Development
Figure 10.18 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Phase of Development
Figure 10.19 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Figure 10.20 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 10.21 Early Stage Pipeline of Gene Therapies: Distribution by Phase of Development
Figure 10.22 Early Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Figure 10.23 Early Stage Pipeline of Gene Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 13.1 Global Cell and Gene Therapy Bioassay Services Market, 2021-2030 (USD Million)
Figure 13.2 Global Cell and Gene Therapy Bioassay Services Market 2021-2030: Distribution by Type of Therapy (USD Million)
Figure 13.3 Global Cell and Gene Therapy Bioassay Services Market 2021-2030: Distribution by Therapeutic Area (USD Million)
Figure 13.4 Global Cell and Gene Therapy Bioassay Services Market 2021-2030: Distribution by Scale of Operation (USD Million)
Figure 13.5 Global Cell and Gene Therapy Bioassay Services Market 2021-2030: Distribution by Geography (USD Million)
Figure 13.6 Cell Therapy Bioassay Services Market in North America, 2021-2030 (USD Million)
Figure 13.7 Cell Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.8 Cell Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Figure 13.9 Cell Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2030 (USD Million)
Figure 13.10 Cell Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2030 (USD Million)
Figure 13.11 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2030 (USD Million)
Figure 13.12 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Figure 13.13 Cell Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2030 (USD Million)
Figure 13.14 Cell Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2030 (USD Million)
Figure 13.15 Cell Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Figure 13.16 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2030 (USD Million)
Figure 13.17 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Figure 13.18 Cell Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.19 Cell Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2030 (USD Million)
Figure 13.20 Cell Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Figure 13.21 Cell Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2030 (USD Million)
Figure 13.22 Cell Therapy Bioassay Services Market in Europe, 2021-2030 (USD Million)
Figure 13.23 Cell Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.24 Cell Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Figure 13.25 Cell Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2030 (USD Million)
Figure 13.26 Cell Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2030 (USD Million)
Figure 13.27 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2030 (USD Million)
Figure 13.28 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Figure 13.29 Cell Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2030 (USD Million)
Figure 13.30 Cell Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2030 (USD Million)
Figure 13.31 Cell Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Figure 13.32 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2030 (USD Million)
Figure 13.33 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Figure 13.34 Cell Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.35 Cell Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2030 (USD Million)
Figure 13.36 Cell Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Figure 13.37 Cell Therapy Bioassay Services Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Figure 13.38 Cell Therapy Bioassay Services Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.39 Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.40 Cell Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.41 Cell Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.42 Cell Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.43 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.44 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.45 Cell Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.46 Cell Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.47 Cell Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.48 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.49 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.50 Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.51 Cell Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.52 Cell Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.53 Cell Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.54 Cell Therapy Bioassay Services Market in Latin America, 2021-2030 (USD Million)
Figure 13.55 Cell Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.56 Cell Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.57 Cell Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2030 (USD Million)
Figure 13.58 Cell Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.59 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.60 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.61 Cell Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.62 Cell Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.63 Cell Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.64 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.65 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2030 (USD Million)
Figure 13.66 Cell Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.67 Cell Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2030 (USD Million)
Figure 13.68 Cell Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2030 (USD Million)
Figure 13.69 Cell Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2030 (USD Million)
Figure 13.70 Cell Therapy Bioassay Services Market in MENA, 2021-2030 (USD Million)
Figure 13.71 Cell Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.72 Cell Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2030 (USD Million)
Figure 13.73 Cell Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2030 (USD Million)
Figure 13.74 Cell Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2030 (USD Million)
Figure 13.75 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2030 (USD Million)
Figure 13.76 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2030 (USD Million)
Figure 13.77 Cell Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2030 (USD Million)
Figure 13.78 Cell Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2030 (USD Million)
Figure 13.79 Cell Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2030 (USD Million)
Figure 13.80 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2030 (USD Million)
Figure 13.81 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2030 (USD Million)
Figure 13.82 Cell Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.83 Cell Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2030 (USD Million)
Figure 13.84 Cell Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2030 (USD Million)
Figure 13.85 Cell Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2030 (USD Million)
Figure 13.86 Gene Therapy Bioassay Services Market in North America, 2021-2030 (USD Million)
Figure 13.87 Gene Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.88 Gene Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Figure 13.89 Gene Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2030 (USD Million)
Figure 13.90 Gene Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2030 (USD Million)
Figure 13.91 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2030 (USD Million)
Figure 13.92 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Figure 13.93 Gene Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2030 (USD Million)
Figure 13.94 Gene Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2030 (USD Million)
Figure 13.95 Gene Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Figure 13.96 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2030 (USD Million)
Figure 13.97 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Figure 13.98 Gene Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.99 Gene Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2030 (USD Million)
Figure 13.100 Gene Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Figure 13.101 Gene Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2030 (USD Million)
Figure 13.102 Gene Therapy Bioassay Services Market in Europe, 2021-2030 (USD Million)
Figure 13.103 Gene Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.104 Gene Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Figure 13.105 Gene Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2030 (USD Million)
Figure 13.106 Gene Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2030 (USD Million)
Figure 13.107 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2030 (USD Million)
Figure 13.108 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Figure 13.109 Gene Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2030 (USD Million)
Figure 13.110 Gene Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2030 (USD Million)
Figure 13.111 Gene Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Figure 13.112 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2030 (USD Million)
Figure 13.113 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Figure 14.114 Gene Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.115 Gene Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2030 (USD Million)
Figure 13.116 Gene Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Figure 13.117 Gene Therapy Bioassay Services Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Figure 13.118 Gene Therapy Bioassay Services Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.119 Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.120 Gene Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.121 Gene Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.122 Gene Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.123 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.124 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.125 Gene Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.126 Gene Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.127 Gene Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.128 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.129 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.130 Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.131 Gene Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.132 Gene Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.133 Gene Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Figure 13.134 Gene Therapy Bioassay Services Market in Latin America, 2021-2030 (USD Million)
Figure 13.135 Gene Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.136 Gene Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.137 Gene Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2030 (USD Million)
Figure 13.138 Gene Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.139 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.140 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.141 Gene Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.142 Gene Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.143 Gene Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.144 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2030 (USD Million)
Figure 13.145 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2030 (USD Million)
Figure 13.146 Gene Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.147 Gene Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2030 (USD Million)
Figure 13.148 Gene Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2030 (USD Million)
Figure 13.149 Gene Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2030 (USD Million)
Figure 13.150 Gene Therapy Bioassay Services Market in MENA, 2021-2030 (USD Million)
Figure 13.151 Gene Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Figure 13.152 Gene Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2030 (USD Million)
Figure 13.153 Gene Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2030 (USD Million)
Figure 13.154 Gene Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2030 (USD Million)
Figure 13.155 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2030 (USD Million)
Figure 13.156 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2030 (USD Million)
Figure 13.157 Gene Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2030 (USD Million)
Figure 13.158 Gene Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2030 (USD Million)
Figure 13.159 Gene Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2030 (USD Million)
Figure 13.160 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2030 (USD Million)
Figure 13.161 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2030 (USD Million)
Figure 13.162 Gene Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2030 (USD Million)
Figure 13.163 Gene Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2030 (USD Million)
Figure 13.164 Gene Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2030 (USD Million)
Figure 13.165 Gene Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2030 (USD Million)
Figure 14.1 Concluding Remarks: Current Market Landscape of Cell and Gene Therapy Bioassay Service providers
Figure 14.2 Concluding Remarks: Global Event and Strategic Analysis
Figure 14.3 Concluding Remarks: Clinical / Preclinical Pipeline of Cell and Gene Therapies
Figure 14.4 Concluding Remarks: Market and Opportunity Analysis

List Of Tables

Table 3.1 List of Approved ATMP Products
Table 4.1 Cell and Gene Therapy Bioassay Services Market: List of Companies
Table 4.2 Cell and Gene Therapy Bioassay Services Market: Information on Type of Bioassay(s) Offered
Table 4.3 Cell and Gene Therapy Bioassay Services Market: Information on Type of Offering(s)
Table 4.4 Cell and Gene Therapy Bioassay Services Market: Information on Type of Bioanalytical Service(s) Offered
Table 4.5 Cell and Gene Therapy Bioassay Services Market: Information on Type of Application Area(s)
Table 6.1 Cell and Gene Therapy Bioassay Service Providers in North America: List of Companies Profiled
Table 6.2 CCRM: Company Snapshot
Table 6.3 CCRM: Cell and Gene Therapy Bioassay Services Offered
Table 6.4 CCRM: Recent Developments and Future Outlook
Table 6.5 Nexelis: Company Snapshot
Table 6.6 Nexelis: Cell and Gene Therapy Bioassay Services Offered
Table 6.7 Nexelis: Recent Developments and Future Outlook
Table 6.8 Pacific BioLabs: Company Snapshot
Table 6.9 Pacific BioLabs: Cell and Gene Therapy Bioassay Services Offered
Table 6.10 Pacific BioLabs: Recent Developments and Future Outlook
Table 6.11 PPD Laboratories: Company Snapshot
Table 6.12 PPD Laboratories: Cell and Gene Therapy Bioassay Services Offered
Table 6.13 PPD Laboratories: Recent Developments and Future Outlook
Table 6.14 WuXi Advanced Therapies: Company Snapshot
Table 6.15 WuXi Advanced Therapies: Cell and Gene Therapy Bioassay Services Offered
Table 6.16 WuXi Advanced Therapies: Recent Developments and Future Outlook
Table 7.1 Cell and Gene Therapy Bioassay Service Providers in Europe and Asia-Pacific: List of Companies Profiled
Table 7.2 AnaBioTec: Company Snapshot
Table 7.3 AnaBioTec: Cell and Gene Therapy Bioassay Services Offered
Table 7.4 AnaBioTec: Recent Developments and Future Outlook
Table 7.5 Intertek Pharmaceutical Services: Company Snapshot
Table 7.6 Intertek Pharmaceutical Services: Recent Developments and Future Outlook
Table 7.7 Intertek Pharmaceutical Services: Cell and Gene Therapy Bioassay Services Offered
Table 7.8 Lonza: Company Snapshot
Table 7.9 Lonza: Cell and Gene Therapy Bioassay Service Portfolio
Table 7.10 Lonza: Recent Developments and Future Outlook
Table 7.11 Porton Bio: Company Snapshot
Table 7.12 Porton Bio: Cell and Gene Therapy Bioassay Services Offered
Table 7.13 Porton Bio: Recent Developments and Future Outlook
Table 9.1 Cell and Gene Therapy Bioassay Service Providers: List of Events and Strategic Initiatives
Table 10.1 CAR-T Cell Therapies: Clinical Pipeline
Table 10.2 CAR-T Cell Therapies: Preclinical Pipeline
Table 10.3 TCR-based Therapies: Clinical Pipeline
Table 10.4 TCR-based Therapies: Information on Sponsor, Type of Developer, Target Antigen, Target Indication and Therapeutic Area
Table 10.5 TIL-based Therapies: Clinical Pipeline
Table 10.6 TIL-based Therapies: Preclinical Pipeline
Table 10.7 Gene Therapy Market: Clinical and Commercial Pipeline
Table 10.8 Gene Therapy Market: Early Stage Pipeline
Table 11.1 Likely Partners for CAR-T Therapy Bioassay Service Providers
Table 11.2 Likely Partners for Stem Cell Therapy Bioassay Service Providers
Table 11.3 Likely Partners for Dendritic Cell Therapy Bioassay Service Providers
Table 11.4 Likely Partners for NK Cell Therapy Bioassay Service Providers
Table 11.5 Likely Partners for Tumor Cell Therapy Bioassay Service Providers
Table 12.1 Likely Partners for Gene Therapy Bioassay Service Providers in North America
Table 12.2 Likely Partners for Gene Therapy Bioassay Service Providers in Europe
Table 12.3 Likely Partners for Gene Therapy Bioassay Service Providers in Asia-Pacific
Table 16.1 Cell and Gene Therapy Bioassay Services Market: Distribution by Year of Establishment
Table 16.2 Cell and Gene Therapy Bioassay Services Market: Distribution by Company Size
Table 16.3 Cell and Gene Therapy Bioassay Services Market: Distribution by Location of Headquarters
Table 16.4 Cell and Gene Therapy Bioassay Services Market: Distribution by Location of Bioanalytical Facilities
Table 16.5 Cell and Gene Therapy Bioassay Services Market: Distribution by Type of Bioassay(s) Offered
Table 16.6 Cell and Gene Therapy Bioassay Services Market: Distribution by Type of Offering(s)
Table 16.7 Cell and Gene Therapy Bioassay Services Market: Distribution by Type of Bioanalytical Service(s) Offered
Table 16.8 Cell and Gene Therapy Bioassay Services Market: Distribution by Application Area(s)
Table 16.9 Company Competitiveness Analysis: Bioassay Service Providers for Cell and Gene Therapies in North America
Table 16.10 Company Competitiveness Analysis: Bioassay Service Providers for Cell and Gene Therapies in Europe and Asia-Pacific
Table 16.11 Cell and Gene Therapy Bioassay Service Providers: Distribution by Type of Bioanalytical Service(s) Offered and Application Area
Table 16.12 Cell and Gene Therapy Bioassay Service Providers: Distribution by Type of Bioassay(s) and Type of Bioanalytical Service(s) Offered
Table 16.13 Cell and Gene Therapy Bioassay Service Providers: Distribution of Players with Bioanalytical Facilities in the US
Table 16.14 Cell and Gene Therapy Bioassay Service Providers: Distribution of Players with Bioanalytical Facilities in Rest of the World
Table 16.15 T-Cell Immunotherapies: Type of Product
Table 16.16 CAR-T Cell Therapies: Distribution by Phase of Development
Table 16.17 CAR-T Cell Therapies: Distribution by Therapeutic Area
Table 16.18 CAR-T Cell Therapies: Distribution by Type of Developer
Table 16.19 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Clinical Development
Table 16.20 CAR-T Cell Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 16.21 TCR-based Therapies: Distribution by Phase of Development
Table 16.22 TCR-based Therapies: Distribution by Therapeutic Area
Table 16.23 TCR-based Therapies: Distribution by Type of Developer
Table 16.24 TCR-based Therapies: Active Industry Players by Number of Therapies in Clinical Development
Table 16.25 TCR-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 16.26 TIL-based Therapies: Distribution by Phase of Development
Table 16.27 TCR-based Therapies: Distribution by Therapeutic Area
Table 16.28 TIL-based Therapies: Distribution by Type of Developer
Table 16.29 TIL-based Therapies: Active Industry Players by Number of Therapies in Clinical Development
Table 16.30 TIL-based Therapies: Active Industry Players by Number of Therapies in Preclinical Development
Table 16.31 Gene Therapies: Distribution by Phase of Development
Table 16.32 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Phase of Development
Table 15.33 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 16.34 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Phase of Development and Therapeutic Area
Table 16.35 Early Stage Pipeline of Gene Therapies: Distribution by Phase of Development
Table 16.36 Early Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 16.37 Early Stage Pipeline of Gene Therapies: Distribution by Phase of Development and Therapeutic Area
Table 16.38 Global Cell and Gene Therapy Bioassay Services Market, 2021-2030 (USD Million)
Table 16.39 Global Cell and Gene Therapy Bioassay Services Market, 2021-2030: Distribution by Type of Therapy (USD Million)
Table 16.40 Global Cell and Gene Therapy Bioassay Services Market 2021-2030: Distribution by Therapeutic Area (USD Million)
Table 16.41 Global Cell and Gene Therapy Bioassay Services Market 2021-2030: Distribution by Scale of Operation (USD Million)
Table 16.42 Global Cell and Gene Therapy Bioassay Services Market 2021-2030: Distribution by Geography (USD Million)
Table 16.43 Cell Therapy Bioassay Services Market in North America, 2021-2030 (USD Million)
Table 16.44 Cell Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.45 Cell Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Table 16.46 Cell Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2030 (USD Million)
Table 16.47 Cell Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2030 (USD Million)
Table 16.48 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2030 (USD Million)
Table 16.49 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Table 16.50 Cell Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2030 (USD Million)
Table 16.51 Cell Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2030 (USD Million)
Table 16.52 Cell Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Table 16.53 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2030 (USD Million)
Table 16.54 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Table 16.55 Cell Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.56 Cell Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2030 (USD Million)
Table 16.57 Cell Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Table 16.58 Cell Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2030 (USD Million)
Table 16.59 Cell Therapy Bioassay Services Market in Europe, 2021-2030 (USD Million)
Table 16.60 Cell Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.61 Cell Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Table 16.62 Cell Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2030 (USD Million)
Table 16.63 Cell Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2030 (USD Million)
Table 16.64 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2030 (USD Million)
Table 16.65 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Table 16.66 Cell Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2030 (USD Million)
Table 16.67 Cell Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2030 (USD Million)
Table 16.68 Cell Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Table 16.69 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2030 (USD Million)
Table 16.70 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Table 16.71 Cell Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.72 Cell Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2030 (USD Million)
Table 16.73 Cell Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Table 16.74 Cell Therapy Bioassay Services Market for Clinical Operations in Europe, 2021 2030 (USD Million)
Table 16.75 Cell Therapy Bioassay Services Market in Asia-Pacific, 2021-2030 (USD Million)
Table 16.76 Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.77 Cell Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.78 Cell Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2030 (USD Million)
Table 16.79 Cell Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.80 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.81 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.82 Cell Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.83 Cell Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.84 Cell Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.85 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.86 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Table 16.87 Cell Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.88 Cell Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 16.89 Cell Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 16.90 Cell Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 16.91 Cell Therapy Bioassay Services Market in Latin America, 2021-2030 (USD Million)
Table 16.92 Cell Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.93 Cell Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2030 (USD Million)
Table 16.94 Cell Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2030 (USD Million)
Table 16.95 Cell Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2030 (USD Million)
Table 16.96 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2030 (USD Million)
Table 16.97 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2030 (USD Million)
Table 16.98 Cell Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2030 (USD Million)
Table 16.99 Cell Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2030 (USD Million)
Table 16.100 Cell Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2030 (USD Million)
Table 16.101 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2030 (USD Million)
Table 16.102 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2030 (USD Million)
Table 16.103 Cell Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.104 Cell Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2030 (USD Million)
Table 16.105 Cell Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2030 (USD Million)
Table 16.106 Cell Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2030 (USD Million)
Table 16.107 Cell Therapy Bioassay Services Market in MENA, 2021-2030 (USD Million)
Table 16.108 Cell Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.109 Cell Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2030 (USD Million)
Table 16.110 Cell Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2030 (USD Million)
Table 16.111 Cell Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2030 (USD Million)
Table 16.112 Cell Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2030 (USD Million)
Table 16.113 Cell Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2030 (USD Million)
Table 16.114 Cell Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2030 (USD Million)
Table 16.115 Cell Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2030 (USD Million)
Table 16.116 Cell Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2030 (USD Million)
Table 16.117 Cell Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2030 (USD Million)
Table 16.118 Cell Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2030 (USD Million)
Table 16.119 Cell Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.120 Cell Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2030 (USD Million)
Table 16.121 Cell Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2030 (USD Million)
Table 16.122 Cell Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2030 (USD Million)
Table 16.123 Gene Therapy Bioassay Services Market in North America, 2021-2030 (USD Million)
Table 16.124 Gene Therapy Bioassay Services Market in North America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.125 Gene Therapy Bioassay Services Market for Oncological Disorders in North America, 2021-2030 (USD Million)
Table 16.126 Gene Therapy Bioassay Services Market for Infectious Diseases in North America, 2021-2030 (USD Million)
Table 16.127 Gene Therapy Bioassay Services Market for Autoimmune Disorders in North America, 2021-2030 (USD Million)
Table 16.128 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in North America, 2021-2030 (USD Million)
Table 16.129 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in North America, 2021-2030 (USD Million)
Table 16.130 Gene Therapy Bioassay Services Market for Metabolic Disorders in North America, 2021-2030 (USD Million)
Table 16.131 Gene Therapy Bioassay Services Market for Blood Disorders in North America, 2021-2030 (USD Million)
Table 16.132 Gene Therapy Bioassay Services Market for Neurological Disorders in North America, 2021-2030 (USD Million)
Table 16.133 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in North America, 2021-2030 (USD Million)
Table 16.134 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in North America, 2021-2030 (USD Million)
Table 16.135 Gene Therapy Bioassay Services Market in North America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.136 Gene Therapy Bioassay Services Market for Discovery Operations in North America, 2021-2030 (USD Million)
Table 16.137 Gene Therapy Bioassay Services Market for Preclinical Operations in North America, 2021-2030 (USD Million)
Table 16.138 Gene Therapy Bioassay Services Market for Clinical Operations in North America, 2021-2030 (USD Million)
Table 16.139 Gene Therapy Bioassay Services Market in Europe, 2021-2030 (USD Million)
Table 16.140 Gene Therapy Bioassay Services Market in Europe: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.141 Gene Therapy Bioassay Services Market for Oncological Disorders in Europe, 2021-2030 (USD Million)
Table 16.142 Gene Therapy Bioassay Services Market for Infectious Diseases in Europe, 2021-2030 (USD Million)
Table 16.143 Gene Therapy Bioassay Services Market for Autoimmune Disorders in Europe, 2021-2030 (USD Million)
Table 16.144 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Europe, 2021-2030 (USD Million)
Table 16.145 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Europe, 2021-2030 (USD Million)
Table 16.146 Gene Therapy Bioassay Services Market for Metabolic Disorders in Europe, 2021-2030 (USD Million)
Table 16.147 Gene Therapy Bioassay Services Market for Blood Disorders in Europe, 2021-2030 (USD Million)
Table 16.148 Gene Therapy Bioassay Services Market for Neurological Disorders in Europe, 2021-2030 (USD Million)
Table 16.149 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Europe, 2021-2030 (USD Million)
Table 16.150 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Europe, 2021-2030 (USD Million)
Table 16.151 Gene Therapy Bioassay Services Market in Europe: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.152 Gene Therapy Bioassay Services Market for Discovery Operations in Europe, 2021-2030 (USD Million)
Table 16.153 Gene Therapy Bioassay Services Market for Preclinical Operations in Europe, 2021-2030 (USD Million)
Table 16.154 Gene Therapy Bioassay Services Market for Clinical Operations in Europe, 2021-2030 (USD Million)
Table 16.155 Gene Therapy Bioassay Services Market in Asia-Pacific, 2021-2030 (USD Million)
Table 16.156 Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.157 Gene Therapy Bioassay Services Market for Oncological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.158 Gene Therapy Bioassay Services Market for Infectious Diseases in Asia-Pacific, 2021-2030 (USD Million)
Table 16.159 Gene Therapy Bioassay Services Market for Autoimmune Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.160 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.161 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.162 Gene Therapy Bioassay Services Market for Metabolic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.163 Gene Therapy Bioassay Services Market for Blood Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.164 Gene Therapy Bioassay Services Market for Neurological Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.165 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Asia-Pacific, 2021-2030 (USD Million)
Table 16.166 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Asia-Pacific, 2021-2030 (USD Million)
Table 16.167 Gene Therapy Bioassay Services Market in Asia-Pacific: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.168 Gene Therapy Bioassay Services Market for Discovery Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 16.169 Gene Therapy Bioassay Services Market for Preclinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 16.170 Gene Therapy Bioassay Services Market for Clinical Operations in Asia-Pacific, 2021-2030 (USD Million)
Table 16.171 Gene Therapy Bioassay Services Market in Latin America, 2021-2030 (USD Million)
Table 16.172 Gene Therapy Bioassay Services Market in Latin America: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.173 Gene Therapy Bioassay Services Market for Oncological Disorders in Latin America, 2021-2030 (USD Million)
Table 16.174 Gene Therapy Bioassay Services Market for Infectious Diseases in Latin America, 2021-2030 (USD Million)
Table 16.175 Gene Therapy Bioassay Services Market for Autoimmune Disorders in Latin America, 2021-2030 (USD Million)
Table 16.176 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in Latin America, 2021-2030 (USD Million)
Table 16.177 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in Latin America, 2021-2030 (USD Million)
Table 16.178 Gene Therapy Bioassay Services Market for Metabolic Disorders in Latin America, 2021-2030 (USD Million)
Table 16.179 Gene Therapy Bioassay Services Market for Blood Disorders in Latin America, 2021-2030 (USD Million)
Table 16.180 Gene Therapy Bioassay Services Market for Neurological Disorders in Latin America, 2021-2030 (USD Million)
Table 16.181 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in Latin America, 2021-2030 (USD Million)
Table 16.182 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in Latin America, 2021-2030 (USD Million)
Table 16.183 Gene Therapy Bioassay Services Market in Latin America: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.184 Gene Therapy Bioassay Services Market for Discovery Operations in Latin America, 2021-2030 (USD Million)
Table 16.185 Gene Therapy Bioassay Services Market for Preclinical Operations in Latin America, 2021-2030 (USD Million)
Table 16.186 Gene Therapy Bioassay Services Market for Clinical Operations in Latin America, 2021-2030 (USD Million)
Table 16.187 Gene Therapy Bioassay Services Market in MENA, 2021-2030 (USD Million)
Table 16.188 Gene Therapy Bioassay Services Market in MENA: Distribution by Therapeutic Area, 2021-2030 (USD Million)
Table 16.189 Gene Therapy Bioassay Services Market for Oncological Disorders in MENA, 2021-2030 (USD Million)
Table 16.190 Gene Therapy Bioassay Services Market for Infectious Diseases in MENA, 2021-2030 (USD Million)
Table 16.191 Gene Therapy Bioassay Services Market for Autoimmune Disorders in MENA, 2021-2030 (USD Million)
Table 16.192 Gene Therapy Bioassay Services Market for Rare / Genetic Disorders in MENA, 2021-2030 (USD Million)
Table 16.193 Gene Therapy Bioassay Services Market for Cardiovascular Disorders in MENA, 2021-2030 (USD Million)
Table 16.194 Gene Therapy Bioassay Services Market for Metabolic Disorders in MENA, 2021-2030 (USD Million)
Table 16.195 Gene Therapy Bioassay Services Market for Blood Disorders in MENA, 2021-2030 (USD Million)
Table 16.196 Gene Therapy Bioassay Services Market for Neurological Disorders in MENA, 2021-2030 (USD Million)
Table 16.197 Gene Therapy Bioassay Services Market for Ophthalmic Disorders in MENA, 2021-2030 (USD Million)
Table 16.198 Gene Therapy Bioassay Services Market for Other Therapeutic Areas in MENA, 2021-2030 (USD Million)
Table 16.199 Gene Therapy Bioassay Services Market in MENA: Distribution by Scale of Operation, 2021-2030 (USD Million)
Table 16.200 Gene Therapy Bioassay Services Market for Discovery Operations in MENA, 2021-2030 (USD Million)
Table 16.201 Gene Therapy Bioassay Services Market for Preclinical Operations in MENA, 2021-2030 (USD Million)
Table 16.202 Gene Therapy Bioassay Services Market for Clinical Operations in MENA, 2021-2030 (USD Million)

List Of Companies

  1. 4D Molecular Therapeutics
  2. AavantiBio
  3. aaVective
  4. AAVogen
  5. AbbVie
  6. AbClon
  7. Abeona Therapeutics
  8. Absorption Systems
  9. Adaptimmune Therapeutics
  10. Adelson Medical Research Foundation (AMRF)
  11. Adicet Bio
  12. Advanced Cell Diagnostics
  13. Advantagene
  14. Advaxis
  15. Adverum Biotechnologies
  16. Aeon Therapeutics
  17. Affinia Therapeutics
  18. AffyImmune Therapeutics
  19. Agency for Science, Technology and Research (A*STAR)
  20. AgenTus Therapeutics
  21. AGTC
  22. AIT Bioscience
  23. Akouos
  24. Allergan
  25. Allogene Therapeutics
  26. AlphaVax
  27. Altasciences
  28. Altheia Science
  29. Altor Bioscience 
  30. Amarna Therapeutics
  31. Ambulero
  32. American Gene Technologies
  33. Amgen
  34. Amicus Therapeutics
  35. AnaBioTec
  36. Anaeropharma Science
  37. AnGes
  38. Angionetics
  39. AnHui Medical University (AHMU)
  40. ApolloBio
  41. Applied StemCell
  42. Arbele
  43. Aruvant Sciences
  44. ASC Therapeutics
  45. Asklepios BioPharmaceutical (AskBio)
  46. Atara Biotherapeutics
  47. Atsena Therapeutics
  48. Aurigon
  49. Aurora Biopharma
  50. Avance Biosciences
  51. Avectas 
  52. Avomeen
  53. AVROBIO
  54. Axovant Gene Therapies
  55. Baylor College of Medicine
  56. BD Biosciences
  57. Beam Therapeutics
  58. Beijing 302 Hospital
  59. Beijing Boren Hospital
  60. Beijing Children's Hospital
  61. Bellicum Pharmaceuticals 
  62. BioAgilytix
  63. BioAnalytix
  64. Biogen
  65. BioMarin Pharmaceutical
  66. BioTether Sciences
  67. BioVec Pharma
  68. bluebird bio
  69. BridgeBio
  70. Bristol-Myers Squibb
  71. California Institute of Technology
  72. Cambridge Gene Therapy
  73. Carmine Therapeutics
  74. Cartesian Therapeutics
  75. Cartherics
  76. Castle Creek Biosciences
  77. Catalent
  78. Catalyst Biosciences
  79. CavoGene LifeSciences
  80. CCRM
  81. Celgene
  82. Cell Therapy Catapult
  83. Cellectis
  84. CellGenTech
  85. Cellular Biomedicine 
  86. Celonic
  87. Celsion
  88. CG Oncology
  89. Changhai Hospital
  90. Charles River Laboratories
  91. Children's Hospital of Philadelphia
  92. China Immunotech Biotechnology
  93. Chinese PLA General Hospital
  94. City of Hope
  95. Clean Cells
  96. CODA Biotherapeutics
  97. Cognate BioServices
  98. CombiGene
  99. Copenhagen University Hospital
  100. Copernicus Therapeutics
  101. Creative Biolabs
  102. CRISPR Therapeutics
  103. CSL Behring
  104. Cynvec
  105. Cyprium Therapeutics
  106. Cytovant Sciences
  107. Daiichi Sankyo 
  108. DiNAQOR
  109. DNAlite Therapeutics
  110. DNAtrix
  111. Duke University School of Medicine
  112. Earle A. Chiles Research Institute
  113. Editas Medicine
  114. Emendo Biotherapeutics
  115. Encoded Therapeutics
  116. Endsulin
  117. Enochian BioSciences
  118. Entos Pharmaceuticals
  119. Epeius Biotechnologies
  120. Errant Gene Therapeutics
  121. Esteve
  122. Eurofins DiscoverX
  123. Evotec
  124. Excision BioTherapeutics
  125. Exegenesis Bio
  126. Expression Therapeutics
  127. Eyevensys
  128. FerGene
  129. Ferring Pharmaceuticals
  130. Flash Therapeutics
  131. Flexion Therapeutics
  132. Fortress Biotech
  133. Fosun Pharma
  134. Fred Hutchinson Cancer Research Center
  135. Freeline Therapeutics
  136. Fujian Cancer Hospital
  137. Fujian Medical University
  138. Gemini Therapeutics
  139. Gene Therapy Research Institution
  140. GeneCure Biotechnologies
  141. Genelux
  142. GeneMedicine
  143. GeneQuine Biotherapeutics
  144. Generation Bio
  145. Genethon
  146. Genocea
  147. Genprex
  148. GenSight Biologics
  149. GenVec
  150. GlaxoSmithKline
  151. Glycostem Therapeutics
  152. GOG Foundation
  153. Gradalis
  154. Gyros Protein Technologies
  155. Gyroscope Therapeutics
  156. Hadassah Medical Organization
  157. Handl Therapeutics
  158. Hebei Senlang Biotechnology
  159. Helixmith
  160. Hemera Biosciences
  161. Henan Cancer Hospital
  162. Henan Provincial People's Hospital
  163. Herantis Pharma
  164. Herlev Hospital
  165. HiTech Health
  166. Holostem Terapie Avanzate
  167. Homology Medicines
  168. HORAMA
  169. Huapont Life Sciences
  170. Human Stem Cells Institute PJSC (HSCI)
  171. Ikarovec
  172. Ilya Pharma
  173. Immatics
  174. Immunocore
  175. ImmunXperts
  176. Immusoft
  177. Incyte
  178. Inovio Pharmaceuticals
  179. Intellia Therapeutics
  180. Intertek
  181. Invectys
  182. Iovance Biotherapeutics
  183. IVERIC bio
  184. James and Esther King Biomedical Research Program
  185. Janssen
  186. JOINN Laboratories 
  187. Jonsson Comprehensive Cancer Center
  188. Juno Therapeutics
  189. Junshi Biosciences 
  190. JW Therapeutics
  191. KAEDI
  192. Karolinska Institute
  193. Key Biologics
  194. Kite Pharma
  195. Kodikaz Therapeutic Solutions
  196. Kolon TissueGene
  197. Kriya Therapeutics
  198. Krystal Biotech
  199. KSQ Therapeutics
  200. Kubota Vision
  201. Kuur Therapeutics
  202. Labcorp
  203. Leiden University Medical Center
  204. LentiStem Biotech
  205. LEXEO Therapeutics
  206. Limelight Bio
  207. Lion TCR
  208. Living Pharma
  209. LogicBio Therapeutics
  210. Lokon Pharma
  211. Lonza
  212. Lysogene
  213. Lytix Biopharma
  214. Masonic Cancer Center
  215. MD Anderson Cancer Center
  216. Medigene
  217. MeiraGTx
  218. Memorial Sloan-Kettering Cancer Center
  219. Merck
  220. Merck KGaA
  221. Mesoblast
  222. Mie University
  223. Milo Biotechnology
  224. Miltenyi Biomedicine
  225. MingJu Therapeutics
  226. Mitsubishi Tanabe Pharma
  227. Momotaro-Gene
  228. MultiVir
  229. Mustang Bio
  230. Myosana Therapeutics
  231. Nanjing Medical University
  232. Nantes University Hospital
  233. National Cancer Institute
  234. Navega Therapeutics
  235. NeuExcell Therapeutics
  236. Neuracle Genetics
  237. Neurogene
  238. Neurophth Therapeutics
  239. Nexelis
  240. Ninevah Therapeutics
  241. Ningbo Cancer Hospital
  242. Noga Therapeutics 
  243. Novartis
  244. Ocugen
  245. Oncolys BioPharma
  246. Onconetics Pharmaceuticals
  247. OncoSec
  248. OncoSenX
  249. ORCA Therapeutics
  250. Orchard Therapeutics
  251. Oxford Biomedica
  252. OXGENE
  253. Oxular
  254. Pacific BioLabs
  255. PACT Pharma
  256. PAIRimmune 
  257. Passage Bio
  258. Pattern Biosciences
  259. PeriphaGen
  260. Peter MacCallum Cancer Centre
  261. Pfizer
  262. Phio Pharmaceuticals
  263. Phoenix Nest
  264. PhorMed
  265. PolyBioCept
  266. Porton Bio
  267. Poseida Therapeutics
  268. PPD Laboratories
  269. Precigen
  270. Precision BioSciences
  271. Precision for Medicine
  272. Prevail Therapeutics
  273. Prometheus Laboratories
  274. Providence
  275. PsiOxus Therapeutics
  276. PTC Therapeutics
  277. Public Health England (PHE)
  278. Q2 Solutions
  279. QualTex Laboratories
  280. R&D systems
  281. Reading Scientific Services
  282. Redbiotec
  283. Redpin Therapeutics
  284. Regeneron Pharmaceuticals
  285. REGENXBIO
  286. Renova Therapeutics
  287. resTORbio
  288. Ring Therapeutics
  289. Rocket Pharmaceuticals
  290. Roswell Park Cancer Institute
  291. Ruijin Hospital
  292. San Raffaele Telethon Institute For Gene Therapy
  293. Sangamo Therapeutics
  294. Sarepta Therapeutics
  295. SBH Sciences
  296. Scancell
  297. Selecta Biosciences
  298. SGS
  299. Shanghai Cell Therapy Research Institute
  300. Shanghai Children's Medical Center
  301. Shanghai Sunway Biotech
  302. Shanghai Unicar-Therapy Bio-medicine Technology
  303. Sheba Medical Center
  304. Shenzhen BinDeBio
  305. Shenzhen Geno-immune Medical Institute
  306. Sibiono GeneTech
  307. Sidney Kimmel Comprehensive Cancer Center
  308. Siemens Healthineers
  309. Sinobioway Cell Therapy
  310. Solid Biosciences
  311. Solvias
  312. Soochow University
  313. Sorrento Therapeutics
  314. Spark Therapeutics
  315. Spirovant Sciences
  316. SpringWorks Therapeutics
  317. St. Jude Children’s Research Hospital
  318. STEMCELL Technologies
  319. StrideBio
  320. Sun Yat-sen University
  321. Svar Life Science
  322. SwanBio Therapeutics
  323. Takara Bio
  324. Targovax
  325. TCR2 Therapeutics
  326. TCRCure Biopharma
  327. Tenaya Therapeutics
  328. Tessa Therapeutics
  329. Texcell
  330. The First Affiliated Hospital of Zhejiang University
  331. The Leukemia and Lymphoma Society
  332. The Methodist Hospital System
  333. The Netherlands Cancer Institute
  334. The Ohio State University Comprehensive Cancer Center 
  335. Pregene Biotechnology
  336. The Seventh Affiliated Hospital
  337. TheraBiologics
  338. THERAVECTYS
  339. Third Military Medical University
  340. Tmunity Therapeutics
  341. Tolerion
  342. TrakCel
  343. Transgene
  344. Trizell
  345. Trucode Gene Repair
  346. UAB (Universitat Autònoma de Barcelona)
  347. Ultragenyx Pharmaceutical
  348. UNC Lineberger Comprehensive Cancer Center 
  349. uniQure
  350. University College London
  351. University Health Network
  352. University of Connecticut
  353. University of Manchester
  354. University of Minnesota
  355. University of Munich
  356. University of Pennsylvania
  357. University of Pittsburgh
  358. University of Southern California
  359. Uppsala University
  360. Urovant Sciences
  361. UWELL Biopharma
  362. VBL Therapeutics
  363. VCN Biosciences
  364. Verve Therapeutics
  365. ViGeneron
  366. Vivet Therapeutics
  367. Voyager Therapeutics
  368. Wellington Zhaotai Therapies
  369. Wize Pharma
  370. WuXi Advanced Therapies
  371. WuXi AppTec
  372. Wyvern Pharmaceuticals
  373. Xiangxue Life Sciences
  374. Xinqiao Hospital
  375. Xuanwu Hospital
  376. XyloCor Therapeutics
  377. Yale University
  378. Zelluna Immunotherapy
  379. Zhujiang Hospital
  380. Ziopharm Oncology

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com